We spend more than $12 billion a year on our pets, most of which goes on their health.
Thing is, like a lot of medications, there can be some pretty distressing side-effects, including nausea, loss of appetite, depression and internal bleeding.
Enter animal-focused pharmaceutical company, CannPal.
Working with the CSIRO, CannPal is researching ways to avoid these negative effects with medicinal cannabis, saying on its website that all mammals have biological and neurological systems that can receive and process nutritional cannabinoids:
“The endocannabinoid system is involved in a variety of physiological processes including appetite, pain-sensation, nausea, mood and memory without some of the side effects that are commonly associated with current treatments for animal health.
“Cannabinoids such as Cannabidiol and Tetrahydrocannabinol (THC) are naturally occurring compounds present in trace amounts in several plants, most notably (though not exclusively) in cannabis. Cannabinoids have been cultivated for thousands of years, in part because they uniquely interact with the ECS.”
Of course, not all animals are made the same — so the meds have to be specifically developed for different animals.
There’s no news on when the research will wrap, let alone when it may or may not hit the mainstream market. However, a dog selection process for a NSW trial was completed in March and dosing occurred in April.